<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Radiocontrast hypersensitivity: Nonimmediate (delayed) reactions</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Radiocontrast hypersensitivity: Nonimmediate (delayed) reactions</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Radiocontrast hypersensitivity: Nonimmediate (delayed) reactions</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Knut Brockow, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">N Franklin Adkinson, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3563588769"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hypersensitivity reactions to both iodinated contrast used in computed tomography (CT), angiography, and urography and gadolinium-based contrast agents (GBCAs) used in magnetic resonance imaging (MRI) are well described. They can be divided into immediate (occurring within minutes to an hour of administration) or nonimmediate (delayed; occurring after hours to days). Nonimmediate reactions are discussed in this topic review. Immediate reactions are reviewed in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2075.html" rel="external">"Diagnosis and treatment of an acute reaction to a radiologic contrast agent"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/118730.html" rel="external">"Allergy evaluation of immediate hypersensitivity reactions to radiocontrast media"</a>.)</p><p></p><p class="headingAnchor" id="H3495277913"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>Nonimmediate hypersensitivity reactions (NIHR), also called delayed hypersensitivity reactions (DHRs), are defined as reactions occurring more than one hour and up to 10 days after contrast administration [<a href="#rid1">1,2</a>]. Understanding of these reactions has been evolving since the earlier reports more than 15 years ago [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H2821680691"><span class="h1">DELAYED REACTIONS TO IODINATED CONTRAST</span></p><p class="headingAnchor" id="H1070696388"><span class="h2">Prevalence</span><span class="headingEndMark"> — </span>The frequency of DHRs to iodinated contrast agents is not well defined. Reported frequencies range from 0.52 to 51 percent for all types and severities of delayed reactions to nonionic monomers [<a href="#rid4">4,5</a>]. However, the majority of studies report delayed cutaneous reaction rates below 4 percent [<a href="#rid6">6</a>]. A prospective comparison of the manifestations observed after enhanced versus unenhanced computed tomography (CT) showed that patients who received contrast reported more skin rashes and redness in the days following the radiologic examination [<a href="#rid5">5-8</a>].</p><p>It is possible that these reactions are underreported because many patients are in the radiology facility only for the procedure and, if the reaction is mild, the patient may not seek medical attention. On the other hand, unrelated events may be incorrectly counted as a DHR if too long a period of time is evaluated by questionnaire.</p><p class="headingAnchor" id="H1680846306"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>A previous DHR to contrast is the greatest predisposing factor for a subsequent DHR [<a href="#rid8">8</a>]. In contrast, a previous immediate reaction to contrast has no bearing on the risk of DHR. Further risk factors for DHR are a history of allergy, particularly another drug allergy or contact allergy [<a href="#rid4">4,9,10</a>]. DHRs can develop after a patient's first exposure to radiocontrast; previous exposure is not required [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H858623662"><span class="h2">Types of reactions</span><span class="headingEndMark"> — </span>The two most common forms of delayed hypersensitivity to radiocontrast are maculopapular exanthema (MPE) [<a href="#rid11">11</a>] and delayed-onset urticaria or angioedema. Both are generally mild and self-limited.</p><p>There are other nonspecific symptoms that can develop in the hours after administration of radiocontrast, including local pain or a wheal at the injection site, generalized pruritus only, transient erythema, headache, dizziness, fever, and/or nausea. These are considered nonspecific reactions, and allergy evaluation is not indicated [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H852308058"><span class="h3">Maculopapular exanthema</span><span class="headingEndMark"> — </span>DHRs most commonly present as macular or maculopapular exanthems occurring &gt;6 hours (and typically approximately 12 hours) to days after contrast administration (<a class="graphic graphic_picture graphicRef129989 graphicRef129990" href="/z/d/graphic/129989.html" rel="external">picture 1A-B</a>). Ten days is generally considered the outer limit of the period in which DHRs to contrast can develop. Symptoms can develop more quickly with subsequent exposures [<a href="#rid13">13</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – These reactions are believed to be T cell mediated, and perivascular infiltrates of CD4+ and CD8+ T cells have been demonstrated [<a href="#rid1">1,14</a>]. In the vast majority of patients, the DHR is directed against the structure of the contrast and only rarely to the iodine ion [<a href="#rid15">15</a>]. However, iodine reactions do occur and usually present with delayed exanthems as well [<a href="#rid15">15,16</a>]. (See <a class="local">'Testing for rare iodine sensitivity'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Often, only topical corticosteroid treatment is required because the reactions are generally mild and resolve spontaneously. Minimally sedating antihistamines can be given to relieve pruritus (eg, <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">cetirizine</a> 10 mg twice daily), and a brief course of oral glucocorticoids can be given for severe exanthema.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis</strong> – The diagnosis of MPE can be made simply based on signs, symptoms, and proximity to radiocontrast administration (<a class="graphic graphic_picture graphicRef129989 graphicRef129990" href="/z/d/graphic/129989.html" rel="external">picture 1A-B</a>). The differential diagnosis includes an exanthem induced by another drug or viral infection, as well as erythema multiforme and pityriasis rosea. Referral to an allergy or dermatology specialist is indicated if additional evaluation is desired. The purpose of an allergy evaluation for MPE is to confirm that the exanthem was related to the contrast and to identify an alternative contrast agent for future use because many patients will be reactive to multiple agents [<a href="#rid17">17</a>]. (See <a class="local">'Allergy evaluation (skin testing and patch testing)'</a> below.)</p><p></p><p class="headingAnchor" id="H1267743148"><span class="h3">Delayed-onset urticaria/angioedema</span><span class="headingEndMark"> — </span>Delayed-onset urticaria or angioedema has been described, especially within the first hours after contrast administration.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – It remains unclear whether these are nonallergic or allergic (late-phase reaction) forms of contrast hypersensitivity. Other possible explanations include incorrectly labeled MPE with some features of urticaria (since the two can be difficult to differentiate in the first hours) or acute urticaria unrelated to contrast media [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – These reactions resolve spontaneously. Minimally sedating antihistamines can be given to relieve pruritus (eg, <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">cetirizine</a> 10 mg twice daily).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis</strong> – Detailed evaluation of this uncommon clinical presentation has not been performed. In our clinic, we perform skin prick testing (SPT) and intradermal testing (IDT) with immediate and delayed readings, as well as patch testing. In many cases, testing is negative, and the radiocontrast agent cannot be confirmed as the culprit. However, in some cases, the reaction was actually an MPE with an urticaria-like appearance, and these reactions can be detected. (See <a class="local">'Allergy evaluation (skin testing and patch testing)'</a> below.)</p><p></p><p class="headingAnchor" id="H1993594698"><span class="h3">Other reactions</span><span class="headingEndMark"> — </span>Other rare forms of DHRs to radiocontrast have been reported, including the following [<a href="#rid1">1,13,18,19</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Fixed drug eruption (FDE) including generalized bullous FDE [<a href="#rid18">18,20,21</a>]. In most cases, the eruptions resolved spontaneously within seven days of onset [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/15760.html" rel="external">"Fixed drug eruption"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symmetrical drug-related intertriginous and flexural exanthema [<a href="#rid22">22,23</a>]. (See  <a class="medical medical_review" href="/z/d/html/2089.html" rel="external">"Drug eruptions", section on 'Symmetrical drug-related intertriginous and flexural exanthema'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute generalized exanthematous pustulosis [<a href="#rid24">24-27</a>]. (See  <a class="medical medical_review" href="/z/d/html/15761.html" rel="external">"Acute generalized exanthematous pustulosis (AGEP)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vasculitis [<a href="#rid28">28,29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Iododerma, a rare and potentially serious neutrophilic dermatosis that can develop after exposure to iodinated contrast media, oral iodide supplements, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, or irrigation of wounds with <a class="drug drug_general" data-topicid="9801" href="/z/d/drug information/9801.html" rel="external">povidone iodine</a> [<a href="#rid13">13,30,31</a>]. Extracutaneous signs and symptoms can include conjunctivitis, salivary gland swelling, and respiratory compromise [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transient angioedema of the small bowel may result in self-limited, mild abdominal discomfort [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug reaction with eosinophilia and systemic symptoms (DRESS) [<a href="#rid33">33-35</a>]. (See  <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) [<a href="#rid36">36,37</a>]. (See  <a class="medical medical_review" href="/z/d/html/2092.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae"</a>.)</p><p></p><p>These reactions range in severity from relatively mild (FDE) to potentially life threatening (TEN). The evaluation and management of these reactions are discussed in the linked topic reviews.</p><p class="headingAnchor" id="H1678386962"><span class="h2">Causative agents</span><span class="headingEndMark"> — </span>Many agents have been associated with DHRs. The dimeric nonionic agent <a class="drug drug_general" data-topicid="8915" href="/z/d/drug information/8915.html" rel="external">iodixanol</a> is associated with more DHRs than other contrast agents, although this is based on limited evidence [<a href="#rid5">5,8,38-40</a>].</p><p class="headingAnchor" id="H2726940070"><span class="h2">Allergy evaluation (skin testing and patch testing)</span><span class="headingEndMark"> — </span>Skin testing with late readings of intradermal sites and patch testing are the two forms of testing that have proven helpful in identifying the responsible contrast agent in DHRs and in choosing alternative agents for future use [<a href="#rid9">9,14,16,17,40-46</a>].</p><p class="headingAnchor" id="H1400794096"><span class="h3">Whom to test and timing</span><span class="headingEndMark"> — </span>Testing is most useful in patients with delayed-onset (ie, from approximately 6 hours to 10 days) MPE that developed after the administration of radiocontrast. We also perform these tests in patients with delayed-onset urticaria/angioedema, but the positivity rate is much lower. Testing takes several days to perform. Patients whose reactions were uncomfortable and who will likely need future radiologic examinations are generally the most motivated to undergo testing.</p><p>Testing should be performed within six months of the index reaction because of a higher sensitivity during this time period [<a href="#rid9">9,47,48</a>]. In a European multicenter study, intradermal tests performed within the first six months after the resolution of DHR showed positive reactions in 48 percent of patients, as opposed to 23 percent in those in whom the time interval between the reaction and IDT was more than six months [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H1359929887"><span class="h3">What to include in testing</span><span class="headingEndMark"> — </span>In the evaluation of patients with past DHRs, we suggest testing with the suspected culprit and some alternatives that are available at the facility where the patient receives care. Iobitridol is often included as a possible alternative because it shows a low cross-reactivity with other agents in patients with DHRs [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H2576315710"><span class="h3">Techniques and interpretation</span><span class="headingEndMark"> — </span>For both delayed exanthema and delayed urticaria/angioedema, we perform SPT with immediate readings and IDT with both immediate and late readings, as well as patch testing.</p><p>We start with SPT with undiluted contrast, primarily to screen for immediate reactivity. SPT is read at 20 minutes and is negative in nearly all cases. If SPT is negative, we perform IDT with a 1:10 dilution [<a href="#rid49">49</a>]. If undiluted contrast is used for IDT, there are more nonspecific irritant reactions at the 20 minute reading, although the sensitivity of late readings in DHRs appears to be higher [<a href="#rid50">50</a>]. Additional data are needed before IDT with undiluted contrast can be recommended as routine practice. IDT is read at 20 minutes and again after 24 or 48 hours and after 72 hours. Any induration with erythema developing after more than six hours is considered to be a positive delayed reaction [<a href="#rid1">1,51</a>]. Patients should also report any later-appearing skin changes at the test site, up to a week later. A more detailed discussion of skin testing is found separately. (See  <a class="medical medical_review" href="/z/d/html/5541.html" rel="external">"Overview of skin testing for IgE-mediated allergic disease"</a>.)</p><p>Concomitantly, patch testing is performed with small pieces of filter paper soaked in undiluted contrast and placed in a 12 mm aluminum Finn chamber, fixed with adhesive tape on the back for 48 hours (two days). The chambers are removed and the test sites read after 48 hours and again after 72 hours [<a href="#rid51">51</a>]. Positives are interpreted using the standard scoring system (<a class="graphic graphic_table graphicRef65159" href="/z/d/graphic/65159.html" rel="external">table 1</a>). A more detailed discussion of patch testing techniques and interpretation is found separately. (See  <a class="medical medical_review" href="/z/d/html/16691.html" rel="external">"Patch testing"</a>.)</p><p class="headingAnchor" id="H2914878317"><span class="h3">Test performance</span></p><p class="bulletIndent1"><span class="glyph">●</span>In a 2015 meta-analysis of studies evaluating skin testing for hypersensitivity reactions to radiocontrast media, the overall positive rate in patients with delayed reactions (any type) on either delayed reading of IDT or patch testing was 26 percent (95% CI 15-41 percent) [<a href="#rid52">52</a>]. The pooled positive rates of SPTs, delayed reading of IDTs, and patch tests were 7, 22, and 16 percent, respectively. The timepoints for delayed readings of IDT differed among studies, but eight studies included at least one or two delayed reading at 24 to 72 hours, sometimes with additional readings out to one week.</p><p></p><p class="bulletIndent1">In six studies on delayed reactions included in the meta-analysis, none reported any false-positive skin test results in 83 exposed and tolerant controls [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1">Estimates of the negative predictive value in patients who were subsequently given the contrast to which they tested negative on delayed reading of IDT have varied across studies, ranging from approximately 53 to 100 percent [<a href="#rid17">17,18,40,41,44-46,53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One of the studies included in the meta-analysis was a 2009 European multicenter prospective study, which included 98 patients with DHRs to contrast [<a href="#rid9">9</a>]. Methods were uniform across all centers and followed the protocols describe above. Patients were evaluated at a median time interval of six months after the clinical reaction and were tested with the suspected culprit contrast agent and a variety of other agents, including ionic monomers, ionic dimers, nonionic monomers, and nonionic dimers [<a href="#rid9">9,12</a>].</p><p></p><p class="bulletIndent1">Results of either delayed IDT or patch testing, or both, were positive in 37 of 98 patients (38 percent), with 32 percent of patients testing positive on the late intradermal reading and 28 percent on the patch test [<a href="#rid9">9</a>]. Skin tests of either type were more often positive when patients were tested within the first six months after the clinical reaction (48 percent) than when tested later (22 percent).</p><p></p><p class="bulletIndent1">The specificity was 100 percent for both IDT with late reading and for patch testing. There were no false-positive tests in 82 healthy controls (71 who had never received contrast and 11 who had tolerated contrast in the past).</p><p></p><p class="headingAnchor" id="H2364241519"><span class="h3">Cross-reactivity</span><span class="headingEndMark"> — </span>There appears to be extensive cross-reactivity based on skin testing results (IDT with delayed readings) among contrast agents in patients with past DHRs [<a href="#rid9">9,41,52</a>]. Most patients test positive to several contrast agents. In the multicenter European study, 25 of the 37 skin test-positive patients were tested with at least seven other agents, and 22 tested positive to several agents [<a href="#rid9">9</a>]. Cross-reactivity is commonly reported between <a class="drug drug_general" data-topicid="8915" href="/z/d/drug information/8915.html" rel="external">iodixanol</a> and <a class="drug drug_general" data-topicid="8927" href="/z/d/drug information/8927.html" rel="external">iohexol</a> and between <a class="drug drug_general" data-topicid="8964" href="/z/d/drug information/8964.html" rel="external">ioversol</a> or <a class="drug drug_general" data-topicid="8932" href="/z/d/drug information/8932.html" rel="external">iopamidol</a> [<a href="#rid53">53</a>] and iomeprol [<a href="#rid9">9,16,41,44-46</a>]. Iobitridol appears to have minimal cross-reactivity with other agents [<a href="#rid46">46,54</a>].</p><p class="headingAnchor" id="H3244127645"><span class="h2">Testing for rare iodine sensitivity</span><span class="headingEndMark"> — </span>In rare cases of MPE to contrast agents, the reaction can be triggered by free iodine or iodide rather than by the radiocontrast media molecule itself. In these cases, prick and patch tests with iodine in petrolatum (0.5 and 1%), iodine in ethanol (0.5%), or iodine dissolved in a mixture of ethanol and water has been performed [<a href="#rid15">15,18</a>]. The optimal testing and challenge strategy has not been determined, and the methods outlined here should be considered preliminary.</p><p class="bulletIndent1"><span class="glyph">●</span>In one publication that included 9 patients with immediate reactions and 10 with delayed reactions, three reactions (one immediate urticaria and two delayed MPEs) were ultimately reproduced with oral challenge to a 5% Lugol's solution (ie, a solution of 5% elemental iodine and 10% potassium iodide in distilled water) [<a href="#rid15">15</a>]. However, Lugol's solution is quite unpalatable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another report, skin tests in two patients were positive to the majority of contrast agents tested and also to iodine tincture (iodine dissolved in a mixture of ethanol and water, resulting in a solution containing 18 to 22 mg/mL iodine and 21 to 26 mg/mL sodium iodide) but negative to Lugol's solution [<a href="#rid18">18</a>]. The clinical relevance of the skin test reaction was tested by repeated topical application (ie, repeated open application testing) of the iodine solutions twice daily for five days onto the outer upper arm or by oral provocation test with 2% Lugol's solution (after excluding thyroid contraindications). In these patients, topical application of iodine tincture resulted in acute allergic contact dermatitis, whereas application of 2% Lugol's solution did not. Patients refused oral challenge with Lugol's solution.</p><p></p><p class="headingAnchor" id="H2443333395"><span class="h2">Investigational tests</span><span class="headingEndMark"> — </span>The lymphocyte transformation test (LTT) measures the proliferation of T cells after stimulation with a drug in vitro. LTT results in DHRs to contrast agents are heterogeneous, and the sensitivity is considered to be moderate [<a href="#rid14">14,44,55-57</a>]. Because of these limitations, the LTT is considered to be an additional diagnostic tool for selected cases but not for routine use.</p><p class="headingAnchor" id="H2998295914"><span class="h2">Challenge procedures (rarely needed)</span><span class="headingEndMark"> — </span>In patients with past DHRs,<strong> </strong>challenge procedures with contrast, although rarely needed, can be used to identify alternative agents that are tolerated [<a href="#rid16">16,40,43-46,58-61</a>]<em>. </em>In patients sensitized to several contrast agents, challenge may be advisable to prove that a certain skin test-negative agent is indeed tolerated [<a href="#rid44">44</a>]. A maximum single challenge dose of 20 to 50 mL appears to be sufficient for excluding recurrent exanthema reactions in response to a future radiologic examination that requires 100 to 150 mL of contrast (the volume considered adequate for a basic radiologic examination).</p><p>The literature contains several approaches to challenges, and consensus regarding the total dose or time intervals used is lacking. Total doses between one-tenth of the required dose up to 100 mL per day and at one hour to one day intervals have been used [<a href="#rid17">17,44-46</a>]. In one study, five patients reacted only after the administration of 25 mL of contrast and six patients after the administration of two doses of 50 mL given within an hourly interval [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H1251464434"><span class="h1">FUTURE ADMINISTRATION OF CONTRAST</span><span class="headingEndMark"> — </span>Patients with past delayed hypersensitivity reactions (DHRs) who have been evaluated by an allergist should receive contrast agents to which they tested negative [<a href="#rid62">62,63</a>]. In patients with past DHRs, <strong>premedication is unlikely to be effective</strong> in preventing recurrence in most cases and therefore not recommended [<a href="#rid41">41,64,65</a>]. However, it may reduce the severity of a subsequent reaction and thus might have a role in certain situations. For example, a case report described a patient with a severe past delayed maculopapular exanthem and positive skin tests to multiple contrast agents in whom glucocorticoids and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> were given prior to administration of a contrast agent to which the patient tested positive, with no recurrence [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H1787391250"><span class="h2">Urgent cases (no time for testing)</span><span class="headingEndMark"> — </span>In cases of urgent need when there is inadequate time to test, using a structurally unrelated contrast medium is associated with a moderately increased risk for a repeat occurrence of exanthema [<a href="#rid16">16,62,63</a>]. There is some evidence that using iobitridol has a very low risk of a repeat reaction, provided that it was not the cause of the patient's index reaction [<a href="#rid16">16,46</a>]. Thus, iobitridol would be the best choice in this situation, if it is available [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H2953973640"><span class="h1">DELAYED REACTIONS TO GADOLINIUM-BASED CONTRAST</span><span class="headingEndMark"> — </span>Very few cases of delayed reactions following gadolinium-based contrast agent (GBCA) administration have been described [<a href="#rid60">60</a>]. In a case report, a 64-year-old woman with a history of past immediate hypersensitivity reactions to iodinated contrast was premedicated with <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> and <a class="drug drug_general" data-topicid="9274" href="/z/d/drug information/9274.html" rel="external">clemastine</a> and given 12 mL of <a class="drug drug_general" data-topicid="8632" href="/z/d/drug information/8632.html" rel="external">gadobutrol</a> 1 mmol/mL prior to undergoing magnetic resonance imaging (MRI) [<a href="#rid67">67</a>]. She was readmitted two days later because of symptoms that began several hours after the GBCA injection, which consisted of exanthema of the face and trunk, palpitations, arrhythmia, and hypertensive episodes (with blood pressure readings up to 220/120 mmHg). The reaction persisted for approximately 12 hours and then resolved without treatment.</p><p>In another case report, a 53-year-old woman developed a generalized eruption of pustules and erythema on intertriginous areas together with mild kidney impairment, malaise, fever, and leukocytosis three days after MRI with a GBCA [<a href="#rid68">68</a>]. Patch tests with undiluted GBCA showed a positive reaction with indurated erythema and pustules to <a class="drug drug_general" data-topicid="8632" href="/z/d/drug information/8632.html" rel="external">gadobutrol</a> and negative skin test results with gadoteric acid.</p><p>Subsequent case reports of patients with maculopapular exanthems have appeared, with and without positive skin tests to GBCA [<a href="#rid69">69-71</a>]. One pediatric case described drug reaction with eosinophilia with systemic symptoms (DRESS) that was attributed to GBCA and which recurred upon reexposure [<a href="#rid70">70</a>].</p><p>In subjects with kidney disease, GBCAs have been associated with nephrogenic systemic fibrosis, a disease resembling scleromyxedema or scleroderma. There is no evidence for an allergic pathogenesis underlying this disease entity. Diagnosis and management are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1955.html" rel="external">"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced kidney disease"</a> and  <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">"Patient evaluation before gadolinium contrast administration for magnetic resonance imaging"</a>.)</p><p class="headingAnchor" id="H3452724636"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/120906.html" rel="external">"Society guideline links: Hypersensitivity to iodinated and gadolinium-based contrast agents"</a>.)</p><p class="headingAnchor" id="H2080162990"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delayed reactions to iodinated contrast</strong> – Nonimmediate hypersensitivity reactions, also called delayed hypersensitivity reactions (DHRs), are defined as reactions that appear later than one hour and up to 10 days after contrast administration. The frequency of all reported DHRs to iodinated contrast is unclear, but most studies suggest that DHRs occur in less than 4 percent of patients. (See <a class="local">'Definition'</a> above and <a class="local">'Prevalence'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Signs, symptoms, and timing</strong> – The most common presentation is a macular or maculopapular exanthem (MPE) appearing between six hours and several days after contrast administration. Delayed-onset urticaria or angioedema can also occur. There are also some rare but serious delayed reactions reported to contrast media, including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and others. (See <a class="local">'Types of reactions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Utility of allergy evaluation</strong> – For patients with a history of an MPE up to 10 days after the administration of radiocontrast, an allergy evaluation can be helpful in confirming that the exanthem was related to the contrast (rather than a viral exanthem, erythema multiforme, or pityriasis rosea). Testing can also identify an alternative contrast agent that is likely to be tolerated for future use because contrast agents show extensive cross-reactivity in their ability to cause DHRs and premedication is generally not effective in preventing recurrent reactions. (See <a class="local">'Maculopapular exanthema'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Components of the evaluation</strong> – Allergy evaluation for a DHR consists of skin testing with late readings and patch testing, which yield positive results in nearly 50 percent of patients when performed within six months of the index reaction. The contrast agent involved in the past reaction should be tested, if known, as well as several possible alternative agents. Iobitridol is often included as a possible alternative because it has low cross-reactivity with other agents. Skin prick testing (SPT) and patch testing are performed with undiluted contrast, and a 1:10 dilution is used for intradermal testing (IDT). IDT sites are examined after 48 and 72 hours, with any induration with erythema developing after 24 hours considered to be a positive reaction.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rare iodine/iodide reactions</strong> – In rare cases of MPE to contrast agents, the reaction can be triggered by free iodine or iodide rather than by the radiocontrast media molecule itself. The optimal testing strategy for this is uncertain. (See <a class="local">'Testing for rare iodine sensitivity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rare reactions to gadolinium-based contrast</strong> – Very few cases of DHRs following gadolinium-based contrast agent (GBCA) administration have been described. Allergy evaluation has been performed as described for iodinated contrast media and has elicited a positive skin test in some cases. (See <a class="local">'Delayed reactions to gadolinium-based contrast'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Brockow K, Christiansen C, Kanny G, et al. Management of hypersensitivity reactions to iodinated contrast media. Allergy 2005; 60:150.</a></li><li><a class="nounderline abstract_t">Bircher AJ, Brockow K, Grosber M, Hofmeier KS. Late elicitation of maculopapular exanthemas to iodinated contrast media after first exposure. Ann Allergy Asthma Immunol 2013; 111:576.</a></li><li><a class="nounderline abstract_t">Brockow K, Becker EW, Worret WI, Ring J. Late skin test reactions to radiocontrast medium. J Allergy Clin Immunol 1999; 104:1107.</a></li><li><a class="nounderline abstract_t">Bellin MF, Stacul F, Webb JA, et al. Late adverse reactions to intravascular iodine based contrast media: an update. Eur Radiol 2011; 21:2305.</a></li><li><a class="nounderline abstract_t">Schild HH, Kuhl CK, Hübner-Steiner U, et al. Adverse events after unenhanced and monomeric and dimeric contrast-enhanced CT: a prospective randomized controlled trial. Radiology 2006; 240:56.</a></li><li><a class="nounderline abstract_t">Yasuda R, Munechika H. Delayed adverse reactions to nonionic monomeric contrast-enhanced media. Invest Radiol 1998; 33:1.</a></li><li><a class="nounderline abstract_t">Loh S, Bagheri S, Katzberg RW, et al. Delayed adverse reaction to contrast-enhanced CT: a prospective single-center study comparison to control group without enhancement. Radiology 2010; 255:764.</a></li><li><a class="nounderline abstract_t">Sohn KH, Kim GW, Lee SY, et al. Immediate and delayed hypersensitivity after intra-arterial injection of iodinated contrast media: a prospective study in patients with coronary angiography. Eur Radiol 2019; 29:5314.</a></li><li><a class="nounderline abstract_t">Brockow K, Romano A, Aberer W, et al. Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. Allergy 2009; 64:234.</a></li><li><a class="nounderline abstract_t">Oi H, Yamazaki H, Matsushita M. Delayed vs. immediate adverse reactions to ionic and non-ionic low-osmolality contrast media. Radiat Med 1997; 15:23.</a></li><li><a class="nounderline abstract_t">Jung KE, Chung J, Park BC, et al. A clinical study of cutaneous adverse reactions to nonionic contrast media in Korea. Ann Dermatol 2012; 24:22.</a></li><li class="breakAll">Torres M, et al. Update ENDA position paper. Allergy 2019 (in preparation).</li><li><a class="nounderline abstract_t">Tasker F, Fleming H, McNeill G, et al. Contrast media and cutaneous reactions. Part 2: Delayed hypersensitivity reactions to iodinated contrast media. Clin Exp Dermatol 2019; 44:844.</a></li><li><a class="nounderline abstract_t">Kanny G, Pichler W, Morisset M, et al. T cell-mediated reactions to iodinated contrast media: evaluation by skin and lymphocyte activation tests. J Allergy Clin Immunol 2005; 115:179.</a></li><li><a class="nounderline abstract_t">Scherer K, Harr T, Bach S, Bircher AJ. The role of iodine in hypersensitivity reactions to radio contrast media. Clin Exp Allergy 2010; 40:468.</a></li><li><a class="nounderline abstract_t">Lerondeau B, Trechot P, Waton J, et al. Analysis of cross-reactivity among radiocontrast media in 97 hypersensitivity reactions. J Allergy Clin Immunol 2016; 137:633.</a></li><li><a class="nounderline abstract_t">Seitz CS, Pfeuffer P, Raith P, et al. Radiocontrast media-associated exanthema: identification of cross-reactivity and tolerability by allergologic testing. Eur J Radiol 2009; 72:167.</a></li><li><a class="nounderline abstract_t">Trautmann A, Brockow K, Behle V, Stoevesandt J. Radiocontrast Media Hypersensitivity: Skin Testing Differentiates Allergy From Nonallergic Reactions and Identifies a Safe Alternative as Proven by Intravenous Provocation. J Allergy Clin Immunol Pract 2019; 7:2218.</a></li><li><a class="nounderline abstract_t">Brockow K. Contrast media hypersensitivity--scope of the problem. Toxicology 2005; 209:189.</a></li><li><a class="nounderline abstract_t">Gavin M, Sharp L, Walker K, et al. Contrast-induced generalized bullous fixed drug eruption resembling Stevens-Johnson syndrome. Proc (Bayl Univ Med Cent) 2019; 32:601.</a></li><li><a class="nounderline abstract_t">Böhm I, Medina J, Prieto P, et al. Fixed drug eruption induced by an iodinated non-ionic X-ray contrast medium: a practical approach to identify the causative agent and to prevent its recurrence. Eur Radiol 2007; 17:485.</a></li><li><a class="nounderline abstract_t">Tan SC, Tan JW. Symmetrical drug-related intertriginous and flexural exanthema. Curr Opin Allergy Clin Immunol 2011; 11:313.</a></li><li><a class="nounderline abstract_t">Arnold AW, Hausermann P, Bach S, Bircher AJ. Recurrent flexural exanthema (SDRIFE or baboon syndrome) after administration of two different iodinated radio contrast media. Dermatology 2007; 214:89.</a></li><li><a class="nounderline abstract_t">Tan CM, Zipursky JS. Acute generalized exanthematous pustulosis caused by an intravenous radiocontrast medium. CMAJ 2020; 192:E1097.</a></li><li><a class="nounderline abstract_t">Hammerbeck AA, Daniels NH, Callen JP. Ioversol-induced acute generalized exanthematous pustulosis: a case report. Arch Dermatol 2009; 145:683.</a></li><li><a class="nounderline abstract_t">Velter C, Schissler C, Moulinas C, et al. Acute generalized exanthematous pustulosis caused by an iodinated contrast radiocontrast medium for computed tomography arthrography of the knee. Contact Dermatitis 2017; 76:371.</a></li><li><a class="nounderline abstract_t">Kim SJ, Lee T, Lee YS, et al. Acute generalized exanthematous pustulosis caused by radiocontrast media. Ann Allergy Asthma Immunol 2010; 105:492.</a></li><li><a class="nounderline abstract_t">Goodfellow T, Holdstock GE, Brunton FJ, Bamforth J. Fatal acute vasculitis after high-dose urography with iohexol. Br J Radiol 1986; 59:620.</a></li><li><a class="nounderline abstract_t">Kerdel FA, Fraker DL, Haynes HA. Necrotizing vasculitis from radiographic contrast media. J Am Acad Dermatol 1984; 10:25.</a></li><li><a class="nounderline abstract_t">Hesseler MJ, Clark MR, Zacur JL, et al. An acneiform eruption secondary to iododerma. JAAD Case Rep 2018; 4:468.</a></li><li><a class="nounderline abstract_t">Chalela JG, Aguilar L. IMAGES IN CLINICAL MEDICINE. Iododerma from Contrast Material. N Engl J Med 2016; 374:2477.</a></li><li><a class="nounderline abstract_t">Wakabayashi T, Sasaoka Y, Sakai Y, et al. Transient Angioedema of the Small Bowel because of Intravenous Nonionic Iodinated Contrast Media. J Pediatr 2021; 230:264.</a></li><li><a class="nounderline abstract_t">George C, Sears A, Selim AG, et al. Systemic hypersensitivity reaction to Omnipaque radiocontrast medium: a case of mini-DRESS. Clin Case Rep 2016; 4:336.</a></li><li><a class="nounderline abstract_t">Belhadjali H, Bouzgarrou L, Youssef M, et al. DRESS syndrome induced by sodium meglumine ioxitalamate. Allergy 2008; 63:786.</a></li><li><a class="nounderline abstract_t">Soria A, Amsler E, Bernier C, et al. DRESS and AGEP Reactions to Iodinated Contrast Media: A French Case Series. J Allergy Clin Immunol Pract 2021; 9:3041.</a></li><li><a class="nounderline abstract_t">Baldwin BT, Lien MH, Khan H, Siddique M. Case of fatal toxic epidermal necrolysis due to cardiac catheterization dye. J Drugs Dermatol 2010; 9:837.</a></li><li><a class="nounderline abstract_t">Savill JS, Barrie R, Ghosh S, et al. Fatal Stevens-Johnson syndrome following urography with iopamidol in systemic lupus erythematosus. Postgrad Med J 1988; 64:392.</a></li><li><a class="nounderline abstract_t">Webb JA, Stacul F, Thomsen HS, et al. Late adverse reactions to intravascular iodinated contrast media. Eur Radiol 2003; 13:181.</a></li><li><a class="nounderline abstract_t">Sutton AG, Finn P, Grech ED, et al. Early and late reactions after the use of iopamidol 340, ioxaglate 320, and iodixanol 320 in cardiac catheterization. Am Heart J 2001; 141:677.</a></li><li><a class="nounderline abstract_t">Hasdenteufel F, Waton J, Cordebar V, et al. Delayed hypersensitivity reactions caused by iodixanol: an assessment of cross-reactivity in 22 patients. J Allergy Clin Immunol 2011; 128:1356.</a></li><li><a class="nounderline abstract_t">Schrijvers R, Breynaert C, Ahmedali Y, et al. Skin Testing for Suspected Iodinated Contrast Media Hypersensitivity. J Allergy Clin Immunol Pract 2018; 6:1246.</a></li><li><a class="nounderline abstract_t">Ahn YH, Koh YI, Kim JH, et al. The potential utility of iodinated contrast media (ICM) skin testing in patients with ICM hypersensitivity. J Korean Med Sci 2015; 30:245.</a></li><li><a class="nounderline abstract_t">Caimmi S, Benyahia B, Suau D, et al. Clinical value of negative skin tests to iodinated contrast media. Clin Exp Allergy 2010; 40:805.</a></li><li><a class="nounderline abstract_t">Torres MJ, Gomez F, Doña I, et al. Diagnostic evaluation of patients with nonimmediate cutaneous hypersensitivity reactions to iodinated contrast media. Allergy 2012; 67:929.</a></li><li><a class="nounderline abstract_t">Vernassiere C, Trechot P, Commun N, et al. Low negative predictive value of skin tests in investigating delayed reactions to radio-contrast media. Contact Dermatitis 2004; 50:359.</a></li><li><a class="nounderline abstract_t">Gracia-Bara MT, Moreno E, Laffond E, et al. Tolerability of iobitridol in patients with non-immediate hypersensitivity reactions to iodinated contrast media. Allergy 2019; 74:195.</a></li><li><a class="nounderline abstract_t">Rosado Ingelmo A, Doña Diaz I, Cabañas Moreno R, et al. Clinical Practice Guidelines for Diagnosis and Management of Hypersensitivity Reactions to Contrast Media. J Investig Allergol Clin Immunol 2016; 26:144.</a></li><li><a class="nounderline abstract_t">Brockow K, Garvey LH, Aberer W, et al. Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2013; 68:702.</a></li><li><a class="nounderline abstract_t">Sánchez-Borges M, Aberer W, Brockow K, et al. Controversies in Drug Allergy: Radiographic Contrast Media. J Allergy Clin Immunol Pract 2019; 7:61.</a></li><li><a class="nounderline abstract_t">Clement O, Dewachter P, Mouton-Faivre C, et al. Immediate Hypersensitivity to Contrast Agents: The French 5-year CIRTACI Study. J EClin Med 2018; 1:51.</a></li><li><a class="nounderline abstract_t">Brockow K, Romano A, Blanca M, et al. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002; 57:45.</a></li><li><a class="nounderline abstract_t">Yoon SH, Lee SY, Kang HR, et al. Skin tests in patients with hypersensitivity reaction to iodinated contrast media: a meta-analysis. Allergy 2015; 70:625.</a></li><li><a class="nounderline abstract_t">Gamboa P, Sánchez de Vicente J, Galán C, et al. Non-immediate hypersensitivity reactions to iomeprol: Diagnostic value of skin tests and cross-reactivity with other iodinated contrast media. Allergy 2022; 77:3641.</a></li><li><a class="nounderline abstract_t">Gaudin O, Deschamps O, Duong TA, et al. Cutaneous tests and interest of iobitridol in non-immediate hypersensitivity to contrast media: a case series of 43 patients. J Eur Acad Dermatol Venereol 2020; 34:e178.</a></li><li><a class="nounderline abstract_t">Lerch M, Keller M, Britschgi M, et al. Cross-reactivity patterns of T cells specific for iodinated contrast media. J Allergy Clin Immunol 2007; 119:1529.</a></li><li><a class="nounderline abstract_t">Torres MJ, Mayorga C, Cornejo-Garcia JA, et al. Monitoring non-immediate allergic reactions to iodine contrast media. Clin Exp Immunol 2008; 152:233.</a></li><li><a class="nounderline abstract_t">Mayorga C, Celik G, Rouzaire P, et al. In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2016; 71:1103.</a></li><li><a class="nounderline abstract_t">Kvedariene V, Martins P, Rouanet L, Demoly P. Diagnosis of iodinated contrast media hypersensitivity: results of a 6-year period. Clin Exp Allergy 2006; 36:1072.</a></li><li><a class="nounderline abstract_t">Della-Torre E, Berti A, Yacoub MR, et al. Proposal of a skin tests based approach for the prevention of recurrent hypersensitivity reactions to iodinated contrast media. Eur Ann Allergy Clin Immunol 2015; 47:77.</a></li><li><a class="nounderline abstract_t">Doña I, Bogas G, Salas M, et al. Hypersensitivity Reactions to Multiple Iodinated Contrast Media. Front Pharmacol 2020; 11:575437.</a></li><li><a class="nounderline abstract_t">Meucci E, Radice A, Fassio F, et al. Diagnostic approach to hypersensitivity reactions to iodinated contrast media: a single-center experience on 98 patients. Eur Ann Allergy Clin Immunol 2020; 52:220.</a></li><li><a class="nounderline abstract_t">Torres MJ, Trautmann A, Böhm I, et al. Practice parameters for diagnosing and managing iodinated contrast media hypersensitivity. Allergy 2021; 76:1325.</a></li><li><a class="nounderline abstract_t">Brockow K. Medical algorithm: Diagnosis and treatment of radiocontrast media hypersensitivity. Allergy 2020; 75:1278.</a></li><li><a class="nounderline abstract_t">Bumbăcea RS, Petruţescu B, Bumbăcea D, Strâmbu I. Immediate and delayed hypersensitivity reactions to intravascular iodine based radiocontrast media -- an update. Pneumologia 2013; 62:47.</a></li><li><a class="nounderline abstract_t">Courvoisier S, Bircher AJ. Delayed-type hypersensitivity to a nonionic, radiopaque contrast medium. Allergy 1998; 53:1221.</a></li><li><a class="nounderline abstract_t">Romano A, Artesani MC, Andriolo M, et al. Effective prophylactic protocol in delayed hypersensitivity to contrast media: report of a case involving lymphocyte transformation studies with different compounds. Radiology 2002; 225:466.</a></li><li><a class="nounderline abstract_t">Boehm I, Heverhagen JT. Delayed reaction following gadolinium-based contrast agent application. Magn Reson Imaging 2018; 50:10.</a></li><li><a class="nounderline abstract_t">Bordel Gómez MT, Martín García C, Meseguer Yebra C, et al. First case report of acute generalized exanthematous pustulosis (AGEP) caused by gadolinium confirmed by patch testing. Contact Dermatitis 2018; 78:166.</a></li><li><a class="nounderline abstract_t">Gauthier A, Mankouri F, Demoly P, Chiriac AM. Nonimmediate Maculopapular Erythema Induced by a Gadolinium-Based Contrast Agent. J Investig Allergol Clin Immunol 2022; 32:226.</a></li><li><a class="nounderline abstract_t">Macías-Iglesias EM, Campanón-Toro MV, Moreno Rodilla E, et al. DRESS Syndrome Induced by a Gadolinium-Based Contrast Agent in a 13-Year-Old Boy. J Investig Allergol Clin Immunol 2022; 32:238.</a></li><li><a class="nounderline abstract_t">Gallardo A, Gracia Bara MT, Moreno EM, et al. Delayed Reaction to Gadobutrol in a Nurse With Myocarditis After SARS-Cov-2 Infection. J Investig Allergol Clin Immunol 2021; 31:358.</a></li></ol></div><div id="topicVersionRevision">Topic 121742 Version 6.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15647034" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Management of hypersensitivity reactions to iodinated contrast media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24267376" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Late elicitation of maculopapular exanthemas to iodinated contrast media after first exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10550760" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Late skin test reactions to radiocontrast medium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21779853" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Late adverse reactions to intravascular iodine based contrast media: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16720865" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Adverse events after unenhanced and monomeric and dimeric contrast-enhanced CT: a prospective randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9438503" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Delayed adverse reactions to nonionic monomeric contrast-enhanced media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20406882" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Delayed adverse reaction to contrast-enhanced CT: a prospective single-center study comparison to control group without enhancement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30937592" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Immediate and delayed hypersensitivity after intra-arterial injection of iodinated contrast media: a prospective study in patients with coronary angiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19178403" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9134581" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Delayed vs. immediate adverse reactions to ionic and non-ionic low-osmolality contrast media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22363151" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A clinical study of cutaneous adverse reactions to nonionic contrast media in Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22363151" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A clinical study of cutaneous adverse reactions to nonionic contrast media in Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31162717" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Contrast media and cutaneous reactions. Part 2: Delayed hypersensitivity reactions to iodinated contrast media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15637566" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : T cell-mediated reactions to iodinated contrast media: evaluation by skin and lymphocyte activation tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20210815" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The role of iodine in hypersensitivity reactions to radio contrast media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26428955" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Analysis of cross-reactivity among radiocontrast media in 97 hypersensitivity reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18620831" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Radiocontrast media-associated exanthema: identification of cross-reactivity and tolerability by allergologic testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30980898" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Radiocontrast Media Hypersensitivity: Skin Testing Differentiates Allergy From Nonallergic Reactions and Identifies a Safe Alternative as Proven by Intravenous Provocation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15767034" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Contrast media hypersensitivity--scope of the problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31656435" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Contrast-induced generalized bullous fixed drug eruption resembling Stevens-Johnson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16937101" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Fixed drug eruption induced by an iodinated non-ionic X-ray contrast medium: a practical approach to identify the causative agent and to prevent its recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21659857" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Symmetrical drug-related intertriginous and flexural exanthema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17191055" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Recurrent flexural exanthema (SDRIFE or baboon syndrome) after administration of two different iodinated radio contrast media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32958574" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Acute generalized exanthematous pustulosis caused by an intravenous radiocontrast medium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19528424" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Ioversol-induced acute generalized exanthematous pustulosis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28497630" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Acute generalized exanthematous pustulosis caused by an iodinated contrast radiocontrast medium for computed tomography arthrography of the knee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21130392" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Acute generalized exanthematous pustulosis caused by radiocontrast media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3708271" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Fatal acute vasculitis after high-dose urography with iohexol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6693595" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Necrotizing vasculitis from radiographic contrast media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29984285" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : An acneiform eruption secondary to iododerma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27332906" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : IMAGES IN CLINICAL MEDICINE. Iododerma from Contrast Material.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33249005" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Transient Angioedema of the Small Bowel because of Intravenous Nonionic Iodinated Contrast Media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27099722" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Systemic hypersensitivity reaction to Omnipaque radiocontrast medium: a case of mini-DRESS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18445196" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : DRESS syndrome induced by sodium meglumine ioxitalamate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33757916" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : DRESS and AGEP Reactions to Iodinated Contrast Media: A French Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20677540" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Case of fatal toxic epidermal necrolysis due to cardiac catheterization dye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3200783" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Fatal Stevens-Johnson syndrome following urography with iopamidol in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12541128" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Late adverse reactions to intravascular iodinated contrast media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11275937" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Early and late reactions after the use of iopamidol 340, ioxaglate 320, and iodixanol 320 in cardiac catheterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21782229" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Delayed hypersensitivity reactions caused by iodixanol: an assessment of cross-reactivity in 22 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29371073" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Skin Testing for Suspected Iodinated Contrast Media Hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25729245" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The potential utility of iodinated contrast media (ICM) skin testing in patients with ICM hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20337646" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clinical value of negative skin tests to iodinated contrast media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22583135" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Diagnostic evaluation of patients with nonimmediate cutaneous hypersensitivity reactions to iodinated contrast media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15274727" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Low negative predictive value of skin tests in investigating delayed reactions to radio-contrast media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30225896" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Tolerability of iobitridol in patients with non-immediate hypersensitivity reactions to iodinated contrast media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27326981" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical Practice Guidelines for Diagnosis and Management of Hypersensitivity Reactions to Contrast Media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23617635" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30573421" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Controversies in Drug Allergy: Radiographic Contrast Media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Immediate Hypersensitivity to Contrast Agents: The French 5-year CIRTACI Study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11991289" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : General considerations for skin test procedures in the diagnosis of drug hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25649510" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Skin tests in patients with hypersensitivity reaction to iodinated contrast media: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35815908" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Non-immediate hypersensitivity reactions to iomeprol: Diagnostic value of skin tests and cross-reactivity with other iodinated contrast media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31814161" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Cutaneous tests and interest of iobitridol in non-immediate hypersensitivity to contrast media: a case series of 43 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17412404" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cross-reactivity patterns of T cells specific for iodinated contrast media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18341616" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Monitoring non-immediate allergic reactions to iodine contrast media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26991315" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16911363" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Diagnosis of iodinated contrast media hypersensitivity: results of a 6-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25951145" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Proposal of a skin tests based approach for the prevention of recurrent hypersensitivity reactions to iodinated contrast media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33071787" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Hypersensitivity Reactions to Multiple Iodinated Contrast Media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31920060" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Diagnostic approach to hypersensitivity reactions to iodinated contrast media: a single-center experience on 98 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33170954" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Practice parameters for diagnosing and managing iodinated contrast media hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31823375" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Medical algorithm: Diagnosis and treatment of radiocontrast media hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23781574" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Immediate and delayed hypersensitivity reactions to intravascular iodine based radiocontrast media -- an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9930602" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Delayed-type hypersensitivity to a nonionic, radiopaque contrast medium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12409581" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Effective prophylactic protocol in delayed hypersensitivity to contrast media: report of a case involving lymphocyte transformation studies with different compounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29540332" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Delayed reaction following gadolinium-based contrast agent application.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29341190" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : First case report of acute generalized exanthematous pustulosis (AGEP) caused by gadolinium confirmed by patch testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34489230" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Nonimmediate Maculopapular Erythema Induced by a Gadolinium-Based Contrast Agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34661534" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : DRESS Syndrome Induced by a Gadolinium-Based Contrast Agent in a 13-Year-Old Boy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33970106" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Delayed Reaction to Gadobutrol in a Nurse With Myocarditis After SARS-Cov-2 Infection.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
